Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Hepatol. Jan 27, 2024; 16(1): 41-53
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.41
Figure 3
Figure 3 The incidence of hepatocellular carcinoma at 12 mo, 24 mo, 36 mo, and 48 mo between the direct-acting antiviral agents treatment group and the non-antiviral treatment group. DAA: Direct-acting antiviral agents.